National Stem Cell President Michael Cohen added, "Dr. Steiner combines over 30 years as a medical professional with an astute background in the financial industry. He has previously served as a medical consultant for a number of publicly traded Fortune 500 companies and will play a pivotal role in helping us become a fully reporting company." With the addition of Dr. Steiner, we look forward to capitalizing on the many commercial opportunities evolving from our productive research and development division."
About National Stem Cell Holding, Inc.
National Stem Cell Holding, Inc. is a biotechnology company emerging
from the R&D stage into the commercialization stage and is focused on
developing therapeutics based upon the use of human cells and their
derivatives. Its mission is to achieve a leadership position in
1) development of cell therapies for disease and injury;
2) stem cell and reproductive cell/tissue laboratory services including
processing and banking; and
3) biomarkers, cell derivatives and cellular proteins.
It is developing a pipeline of proprietary cell therapeutics with
particular focus on diabetes and cardiac disease. Many of the currently
incurable diseases associated with aging are caused by the degeneration of
specific cell types in the body. These include but are not limited to:
cancer, heart disease, diabetes, and auto immune conditions. Cell Therapy
involves the introduction of healthy new cells to repair and replace
damaged or lost cells. This therapy often referred to as "Regenerative
Medicine" or "Cellular Medicine" provides much promise for the treatment of
diseases previously regarded as incurable. In addition to its work with
stem cell therapeutics, National Stem Cell is also working to leverage its
commercial infrastructure and product development capabilities. Its
investigational products are focused on the improvement of the quality of
|SOURCE National Stem Cell Holding, Inc.|
Copyright©2008 PR Newswire.
All rights reserved